{
    "nct_id": "NCT04524871",
    "official_title": "A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)",
    "inclusion_criteria": "Stage 1\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 within 7 days prior to randomization\n* Locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of\n* Liver Diseases criteria in cirrhotic patients\n* Child-Pugh class A within 7 days prior to randomization\n* Disease that is not amenable to curative surgical and/or locoregional therapies\n* No prior systemic treatment for HCC\n* Life expectancy >= 3 months\n* Availability of a representative tumor specimen that is suitable for determination of PD-L1 and/or additional biomarker status via central testing\n\nStage 1 and Stage 2\n\n* Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1\n* Adequate hematologic and end-organ function within 7 days prior to initiation of study treatment\n* Documented virology status of hepatitis, as confirmed by screening tests for hepatitis B virus - (HBV) and hepatitis C virus (HCV)\n* Negative HIV test at screening\n* For women of childbearing potential: agreement to remain abstinent or use contraception and for men: agreement to remain abstinent or use contraception, and agreement to refrain from donating sperm\n\nStage 2\n\n* ECOG Performance Status of 0, 1, or 2\n* Ability to initiate Stage 2 treatment within 3 months after experiencing unacceptable toxicity not related to atezolizumab or RO7247669 or loss of clinical benefit as determined by the investigator while receiving Stage 1 treatment\n* Availability of a tumor specimen from a biopsy performed upon discontinuation of Stage 1 (if deemed clinically feasible)\n\nNKT2152-Containing Arm:\n\n* Total bilirubin ≤ 1.5 X ULN in the absence of Gilbert's disease (≤ 3.0 X ULN if Gilbert's disease)\n* AST/ALT ≤ 2.5 X ULN (≤ 5 X ULN if liver metastases present)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Stage 1\n\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies or inhibitors targeting HIF2a\n* Treatment with investigational therapy within 28 days prior to initiation of study\n* Treatment with locoregional therapy to liver within 28 days prior to initiation of study, or non-recovery from side effects of any such procedure\n* Untreated or incompletely treated esophageal and/or gastric varices with bleeding or at high risk for bleeding\n* Prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study\n* AEs from prior anti-cancer therapy that have not resolved to Grade <= 1 or better, with the exception of alopecia of any grade\n* Inadequately controlled hypertension\n* History of hypertensive crisis or hypertensive encephalopathy\n* Significant vascular disease\n* History of hemoptysis within 1 month prior to initiation of study\n* Evidence of bleeding diathesis or significant coagulopathy\n* Current or recent use of aspirin (>325 mg/day) or treatment with clopidogrel, dipyramidole, ticlopidine, or cilostazol\n* Current or recent use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose\n* Core biopsy or other minor surgical procedure within 3 days prior to initiation of study\n* History of abdominal or tracheoesophageal fistula, GI perforation, or intra-abdominal abscess, intestinal obstruction and/or clinical signs/symptoms of GI obstruction\n* Evidence of abdominal free air not explained by paracentesis or recent surgery\n* Serious, non-healing/dehiscing wound, active ulcer, or untreated bone fracture\n* Grade >=2 proteinuria\n* Metastatic disease involving major airways/blood vessels, or centrally located mediastinal tumor masses of large volume\n* History of clinically significant intra-abdominal inflammatory process\n* Radiotherapy within 28 days or abdominal/pelvic radiotherapy within 60 days prior to initiation of study with the exception of palliative radiotherapy to bone lesions within 7 days prior to initiation of study\n* Major surgery, open biopsy, or significant traumatic injury within 28 days prior to initiation of study; or abdominal surgery, abdominal interventions or significant abdominal traumatic injury within 60 days prior to initiation of study; or anticipation of need for major surgery during study or non-recovery from side effects of any such procedure\n* Chronic daily treatment with NSAID\n* Eligible only for control arm\n\nStage 1 and 2\n\n* Fibrolamellar or sarcomatoid HCC, or mixed cholangiocarcinoma and HCC\n* History of hepatic encephalopathy\n* Moderate or severe ascites\n* HBV and HCV coinfection\n* Symptomatic, untreated, or actively progressing CNS metastases\n* History of leptomeningeal disease\n* Uncontrolled tumor-related pain\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures\n* Uncontrolled or symptomatic hypercalcemia\n* Active or history of autoimmune disease or immune deficiency\n* History of IPF, organizing pneumonia, drug-induced or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan\n* Active TB\n* Significant CV disease within 3 months prior to initiation of study, unstable arrhythmia, or unstable angina\n* Major surgery, other than for diagnosis, within 4 weeks prior to initiation of study, or anticipated major surgery during study\n* History of malignancy other than HCC within 5 years prior to screening\n* Severe infection within 4 weeks prior to initiation of study\n* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study\n* Prior allogeneic stem cell or solid organ transplantation\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab\n* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins\n* Known allergy or hypersensitivity to any of the study drugs or any of their excipients\n* Treatment with systemic immunostimulatory, immunosuppressive agents within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study\n* Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study\n* Grade >= 3 hemorrhage or bleeding event within 8 weeks prior to initiation of study treatment\n* Patients entering Stage 2: immunotherapy-related adverse events that have not resolved to Grade 1 or better or to baseline at time of consent",
    "miscellaneous_criteria": ""
}